Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Analytical and characterisation instruments / Sequencing and single-cell spatial characterisation platforms
Sequencing and single-cell spatial characterisation platforms
Sequencing, imaging and single-cell analysis platforms bought by pharmaceutical and biotechnology companies, contract research organisations and academic research institutions to characterise genomes, transcriptomes, cell states and tissue architecture for target discovery, mechanism-of-action studies, biomarker development and translational research. Excludes instruments bought primarily for regulated manufacturing quality control or clinical diagnostic reporting.
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Genomics, translational medicine and cell biology teams in pharmaceutical and biotechnology companies; genomics and single-cell service lines in contract research organisations; genomics and imaging research groups in academic research institutions
- Buying centre
- Genomics or translational research leadership, supported by laboratory directors, bioinformatics, data science and procurement; academic purchases are typically decided by principal investigators with committee or grant-office approval
- Launch or expansion of a genomics, single-cell or spatial biology programme
- Need to resolve target mechanism, patient segment or biomarker hypothesis
- Access and throughput limits of an existing sequencing core become a programme bottleneck
- Replacement of an ageing sequencer, cytometer or imaging platform
- Large instrument and facility costs, with specialist operating and bioinformatic talent requirements
- Data generation outpaces storage, compute and bioinformatics capacity
- Batch effects and platform differences complicate cross-study comparison
- Instrument utilisation is difficult to optimise when workflows are shared across projects
How this was sized
Not sized yet
No source provides a revenue pool for this buyer-defined niche. Indicative arithmetic only: global life science tools revenue of USD 184.3 billion in 2025 [1] multiplied by an assumed 15% share for sequencing platforms and the sequencing-related consumables needed to run them gives USD 27.65 billion, then by an assumed 35% share for the specified buyers gives USD 9.68 billion (27.65 x 0.35). Bottom-up, Low confidence: the consumables share is an assumption, the 15% allocation is not verified, and the tools-market source is broader than the specified analytical and characterisation instrument scope.
- Life Science Tools Market Size & Share Report, 2026-2033
grandviewresearch.com · 2026-09-10
Alongside it in Analytical and characterisation instruments
// Sell into Sequencing and single-cell spatial characterisation platforms